Tumor Suppression
On April 20, Dong-A ST announced the results of a preclinical study of its immuno-oncology drug candidate “DA-4505” at the American Association for Cancer Research (AACR) 2023 held in Orlando, Florida in the United States from April 14 to 19.
At this meeting, Dong-A ST presented the anti-tumor effects of DA-4505, a novel aryl hydrocarbon receptor antagonist, as an immunotherapeutic agent in the tumor microenvironment and the anti-tumor effects of DA-4505, a new AhR antagonist, to improve the efficacy of anti-cancer surgery and chemotherapy as a poster.
DA-4505 is an aryl hydrocarbon receptor (AhR) antagonist. AhRs regulate the immune system and play a role in suppressing immune responses and preventing tumor cells from being attacked.
In preclinical studies, DA-4505 inhibited AhRs and restored suppressed immune responses in the tumor microenvironment. In addition, it activates stimulating immune cells such as dendritic cells and T cells and reduces cancer cells’ ability to suppress immunity.
In particular, improved tumor suppression effects were confirmed through preclinical studies comparing DA-4505 with AhR antagonists being developed by global pharmaceutical giants. In addition, the combined administration of DA-4505 and a global pharmaceutical company’s anti-PD-1 immune checkpoint inhibitor confirmed increased tumor suppression effects.